  {"id":34837,"date":"2015-05-20T07:48:25","date_gmt":"2015-05-20T17:48:25","guid":{"rendered":"http:\/\/www.hawaii.edu\/news\/?p=34837"},"modified":"2021-08-31T15:07:26","modified_gmt":"2021-09-01T01:07:26","slug":"ebola-vaccine-focus-of-uh-and-hawaii-biotech-partnership","status":"publish","type":"post","link":"https:\/\/www.hawaii.edu\/news\/2015\/05\/20\/ebola-vaccine-focus-of-uh-and-hawaii-biotech-partnership\/","title":{"rendered":"Ebola vaccine focus of <abbr title=\"University of Hawaii\">糖心Vlog官方<\/abbr> and Hawai\u02bbi Biotech partnership"},"content":{"rendered":"<span class=\"span-reading-time rt-reading-time\" style=\"display: block;\"><span class=\"rt-label rt-prefix\">Reading time: <\/span> <span class=\"rt-time\"> 2<\/span> <span class=\"rt-label rt-postfix\">minutes<\/span><\/span><figure id=\"attachment_34941\" aria-describedby=\"caption-attachment-34941\" style=\"width: 630px\" class=\"wp-caption alignleft\"><img loading=\"lazy\" decoding=\"async\" src=\"http:\/\/www.hawaii.edu\/news\/wp-content\/uploads\/2015\/05\/lehrer-a.jpg\" alt=\"\" width=\"620\" height=\"413\" class=\"size-full wp-image-34941\" srcset=\"https:\/\/www.hawaii.edu\/news\/wp-content\/uploads\/2015\/05\/lehrer-a.jpg 620w, https:\/\/www.hawaii.edu\/news\/wp-content\/uploads\/2015\/05\/lehrer-a-260x173.jpg 260w\" sizes=\"auto, (max-width: 620px) 100vw, 620px\" \/><figcaption id=\"caption-attachment-34941\" class=\"wp-caption-text\">Axel Lehrer was the expert <span aria-label=\"Hawaii\">Hawai&#699;i<\/span> media turned to when ebola struck last year.<\/figcaption><\/figure>\n<p>The <a href=\"http:\/\/jabsom.hawaii.edu\/\">John A. Burns School of Medicine<\/a> (<abbr>JABSOM<\/abbr>), <a href=\"http:\/\/manoa.hawaii.edu\/\">University of <span aria-label=\"Hawaii\">Hawai&#699;i<\/span> at M&#257;noa<\/a> and <a href=\"http:\/\/www.hibiotech.com\/\"><span aria-label=\"Hawaii\">Hawai&#699;i<\/span> Biotech, Inc.<\/a> (<abbr>HBI<\/abbr>) have agreed to partner in the clinical development of a filovirus vaccine. The first generation recombinant subunit vaccine is aimed at providing protection against infection by the Ebola virus. There are currently no vaccines licensed for use against Ebola Virus Disease and other diseases caused by closely related viruses. Ebola vaccine candidates currently in clinical development have yet to demonstrate safety and efficacy in humans to gain regulatory approval.<\/p>\n<h2>Bringing vaccine into clinical studies<\/h2>\n<p>The filovirus vaccine was originally developed by <strong>Axel Lehrer<\/strong> and others at <abbr>HBI<\/abbr> while Lehrer was an employee with the company. Last year, Lehrer assumed a position with <abbr>糖心Vlog官方<\/abbr> M&#257;noa, which allowed him to continue his important work on the development of the vaccine candidate within the <abbr>JABSOM<\/abbr> <a href=\"http:\/\/manoa.hawaii.edu\/tropicalmedicine\/\">Department of Tropical Medicine, Medical Microbiology and Pharmacology<\/a>. Based upon promising results from testing the recombinant Ebola vaccine candidate in animal models (this testing occurred on the U.S. mainland via collaborations with several biosafety laboratories) and the renewed interest in a safe and effective Ebola vaccine triggered by the current Ebola outbreak in West Africa, <abbr>JABSOM<\/abbr>, <abbr>糖心Vlog官方<\/abbr> M&#257;noa and <abbr>HBI<\/abbr> have agreed to join forces to bring this vaccine into clinical studies. While the initial vaccine to be tested in humans is designed to protect against the Ebola virus alone, research at <abbr>JABSOM<\/abbr> and <abbr>HBI<\/abbr> is underway to formulate a trivalent vaccine that will also protect against two other closely related filoviruses, the Sudan virus and the Marburg virus.<\/p>\n<p>&ldquo;This partnership will leverage the research capability and the expertise in tropical medicine here at <abbr>JABSOM<\/abbr> with <abbr>HBI<\/abbr>&#8217;s experience in developing commercially viable vaccines against viruses that infect humans,&rdquo; said <strong>Vivek R. Nerurkar<\/strong>, professor and chair of the Department of Tropical Medicine, Medical Microbiology and Pharmacology and director of the <abbr>JABSOM<\/abbr> Biocontainment Facility at <abbr>糖心Vlog官方<\/abbr> M&#257;noa.<\/p>\n<p>&ldquo;We are delighted to be working closely with the Department of Tropical Medicine at <abbr>糖心Vlog官方<\/abbr> M&#257;noa and contributing our long-standing experience in developing subunit vaccines to protect against hemorrhagic and neuro-invasive viruses,&rdquo; said Elliot Parks, <abbr>CEO<\/abbr> of <abbr>HBI<\/abbr>. &ldquo;Ours is a productive partnership with <abbr>糖心Vlog官方<\/abbr> M&#257;noa which mutually strengthens our respective contributions to this joint vaccine development program. This joint collaboration furthers our goal to continue development of vaccines for emerging infectious diseases.&rdquo;<\/p>\n<h2>Goal is a safe and effective Ebola vaccine<\/h2>\n<p>Under this partnership, <abbr>HBI<\/abbr> will contribute commercial expertise in the manufacture of this vaccine and its components, quality assurance and control, clinical conduct, and regulatory affairs. The ultimate goal is a safe and effective Ebola vaccine to protect humans from this dangerous, and too often lethal, virus causing hemorrhagic fevers.<\/p>\n<p>Lehrer, the principal investigator, added, &ldquo;I am pleased to have the opportunity to continue research on this vaccine candidate within the Department of Tropical Medicine, Medical Microbiology and Pharmacology at <abbr>糖心Vlog官方<\/abbr> M&#257;noa. Retaining a relationship with <abbr>HBI<\/abbr> and its talented team whom I know well will help to assure continuity with the advanced development activities. <abbr>HBI<\/abbr>&#8217;s commercial sensibilities will complement the academic research environment at <abbr>糖心Vlog官方<\/abbr> M&#257;noa&rdquo;.<\/p>\n<p><em>&#8212;By Tina Shelton<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Hawaii Biotech to serve as commercial partner for <abbr>糖心Vlog官方<\/abbr> M&#257;noa program<\/p>\n","protected":false},"author":16,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[30],"tags":[1227,165,31,429,9],"class_list":["post-34837","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-research","tag-ebola","tag-health","tag-john-a-burns-school-of-medicine","tag-tropical-medicine-and-medical-microbiology","tag-uh-manoa","entry","has-media"],"aioseo_notices":[],"jetpack_featured_media_url":"","_links":{"self":[{"href":"https:\/\/www.hawaii.edu\/news\/wp-json\/wp\/v2\/posts\/34837","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.hawaii.edu\/news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.hawaii.edu\/news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.hawaii.edu\/news\/wp-json\/wp\/v2\/users\/16"}],"replies":[{"embeddable":true,"href":"https:\/\/www.hawaii.edu\/news\/wp-json\/wp\/v2\/comments?post=34837"}],"version-history":[{"count":17,"href":"https:\/\/www.hawaii.edu\/news\/wp-json\/wp\/v2\/posts\/34837\/revisions"}],"predecessor-version":[{"id":147300,"href":"https:\/\/www.hawaii.edu\/news\/wp-json\/wp\/v2\/posts\/34837\/revisions\/147300"}],"wp:attachment":[{"href":"https:\/\/www.hawaii.edu\/news\/wp-json\/wp\/v2\/media?parent=34837"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.hawaii.edu\/news\/wp-json\/wp\/v2\/categories?post=34837"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.hawaii.edu\/news\/wp-json\/wp\/v2\/tags?post=34837"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}